Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin
Leander Grode, … , Bärbel Raupach, Stefan H.E. Kaufmann
Leander Grode, … , Bärbel Raupach, Stefan H.E. Kaufmann
Published September 1, 2005
Citation Information: J Clin Invest. 2005;115(9):2472-2479. https://doi.org/10.1172/JCI24617.
View: Text | PDF
Research Article Infectious disease Article has an altmetric score of 28

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

  • Text
  • PDF
Abstract

The tuberculosis vaccine Mycobacterium bovis bacille Calmette-Guérin (BCG) was equipped with the membrane-perforating listeriolysin (Hly) of Listeria monocytogenes, which was shown to improve protection against Mycobacterium tuberculosis. Following aerosol challenge, the Hly-secreting recombinant BCG (hly+ rBCG) vaccine was shown to protect significantly better against aerosol infection with M. tuberculosis than did the parental BCG strain. The isogenic, urease C–deficient hly+ rBCG (ΔureC hly+ rBCG) vaccine, providing an intraphagosomal pH closer to the acidic pH optimum for Hly activity, exhibited still higher vaccine efficacy than parental BCG. ΔureC hly+ rBCG also induced profound protection against a member of the M. tuberculosis Beijing/W genotype family while parental BCG failed to do so consistently. Hly not only promoted antigen translocation into the cytoplasm but also apoptosis of infected macrophages. We concluded that superior vaccine efficacy of ΔureC hly+ rBCG as compared with parental BCG is primarily based on improved cross-priming, which causes enhanced T cell–mediated immunity.

Authors

Leander Grode, Peter Seiler, Sven Baumann, Jürgen Hess, Volker Brinkmann, Ali Nasser Eddine, Peggy Mann, Christian Goosmann, Silke Bandermann, Debbie Smith, Gregory J. Bancroft, Jean-Marc Reyrat, Dick van Soolingen, Bärbel Raupach, Stefan H.E. Kaufmann

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 Total
Citations: 3 12 10 17 8 11 6 11 14 12 13 22 7 17 17 16 9 10 9 5 1 230
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (230)

Title and authors Publication Year
Tuberculosis vaccines and therapeutic drug: challenges and future directions
An Y, Ni R, Zhuang L, Yang L, Ye Z, Li L, Parkkila S, Aspatwar A, Gong W
Molecular Biomedicine 2025
Cross-District Transmission of Tuberculosis in a High-Mobility City in China: Implications for Regional Collaboration in Infectious Disease Control
Hong C, Ge J, Gui J, Che X, Li Y, Zhuo Z, Li M, Wang F, Tan W, Zhao Z
Infection and Drug Resistance 2025
A review of the efficacy of clinical tuberculosis vaccine candidates in mouse models
del Pozo-Ramos L, Kupz A
Frontiers in Immunology 2025
Bladder Cancer: Immunotherapy and Pelvic Lymph Node Dissection
Fan Z, Deng J, Wang Y, Fan X, Xie J
Human vaccines 2024
Vaccine development: obligate intracellular bacteria new tools, old pathogens: the current state of vaccines against obligate intracellular bacteria.
van Schaik EJ, Fratzke AP, Gregory AE, Dumaine JE, Samuel JE
Frontiers in Cellular and Infection Microbiology 2024
Live Attenuated Vaccines against Tuberculosis: Targeting the Disruption of Genes Encoding the Secretory Proteins of Mycobacteria
Veerapandian R, Gadad SS, Jagannath C, Dhandayuthapani S
Human vaccines 2024
Tuberculosis Vaccines and T Cell Immune Memory.
Li F, Dang W, Du Y, Xu X, He P, Zhou Y, Zhu B
Human vaccines 2024
Mycobacterium tuberculosis–Human Immunodeficiency Virus Infection and the Role of T Cells in Protection
Hosseinian K, Gerami A, Bral M, Venketaraman V
Human vaccines 2024
Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment
Journal of Zhejiang University. Science. B 2024
The whole genome sequence of Polish vaccine strain Mycobacterium bovis BCG Moreau
Krysztopa-Grzybowska K, Lach J, Polak M, Strapagiel D, Dziadek J, Olszewski M, Zasada AA, Darlińska A, Lutyńska A, Augustynowicz-Kopeć E
Microbiology spectrum 2024
The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines against Mycobacterium tuberculosis
Ari MM, Beig M, Sholeh M, Khoshmirsafa M
Clinical and Experimental Vaccine Research 2024
The danger theory of immunity revisited.
Kroemer G, Montégut L, Kepp O, Zitvogel L
Nature reviews. Immunology 2024
Macrophages directly kill bladder cancer cells through TNF signaling as an early response to BCG therapy.
Martínez-López MF, de Almeida CR, Fontes M, Mendes RV, Kaufmann SHE, Fior R
Disease models & mechanisms 2024
An mRNA vaccine induces antimycobacterial immunity by activating DNA damage repair and autophagy
Chen D, Huang W, Shen L, Zhang J, Pan Z, Zhang C, Tang Y, Zhou Z, Tao J, Luo G, Zhang S, Zhou J, Xu S, Zhang M, Li Y, Fang Y, Zhao F, Huang L, Li H, Yang H, Lv H, Sha W, Yan B, Liu J, Zhang L
Molecular Therapy. Nucleic Acids 2024
Dendritic Cell Vaccine Harboring Inactivated Mycobacteria Induces Immune Protection Against Tuberculosis in Murine Models and is Well Tolerated in Humans
Hu Z, Liu X, Wang J, Gu L, Chen Z, Xia L, Yang H, Xu J, Huang X, Wang H, Lu S, Fan X
Small Science 2024
Role of MHC class I pathways in Mycobacterium tuberculosis antigen presentation
Witt KD
Frontiers in Cellular and Infection Microbiology 2023
Safety and Immunogenicity of Recombinant Bacille Calmette-Guérin Strain VPM1002 and Its Derivatives in a Goat Model
Figl J, Köhler H, Wedlich N, Liebler-Tenorio EM, Grode L, Parzmair G, Krishnamoorthy G, Nieuwenhuizen NE, Kaufmann SH, Menge C
International journal of molecular sciences 2023
Vaccines against Tuberculosis: Where Are We Now?
Srivastava S, Dey S, Mukhopadhyay S
Human vaccines 2023
Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)
Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas R
BMJ Open 2023
The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria
Khalid K, Poh CL
Human vaccines 2023
BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine
Perera DJ, Domenech P, Babuadze GG, Naghibosadat M, Alvarez F, Koger-Pease C, Labrie L, Stuible M, Durocher Y, Piccirillo CA, Lametti A, Fiset PO, Elahi SM, Kobinger GP, Gilbert R, Olivier M, Kozak R, Reed MB, Ndao M
iScience 2023
Host-directed therapy for bacterial infections -Modulation of the phagolysosome pathway-
Taya T, Teruyama F, Gojo S
Frontiers in immunology 2023
Key advances in vaccine development for tuberculosis—success and challenges
Lai R, Ogunsola AF, Rakib T, Behar SM
npj Vaccines 2023
Vaccine development against tuberculosis before and after Covid-19
Kaufmann SH
Frontiers in immunology 2023
Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist.
Um PK, Praharaj M, Lombardo KA, Yoshida T, Matoso A, Baras AS, Zhao L, Srikrishna G, Huang J, Prasad P, Kates M, McConkey D, Pardoll DM, Bishai WR, Bivalacqua TJ
bioRxiv : the preprint server for biology 2023
Mycobacterium tuberculosis impedes CD40-dependent notch signaling to restrict Th17 polarization during infection
A Enriquez, J Sia, H Dkhar, S Goh, M Quezada, K Stallings, J Rengarajan
iScience 2022
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer
A Singh, M Praharaj, K Lombardo, T Yoshida, A Matoso, A Baras, L Zhao, G Srikrishna, J Huang, P Prasad, J Powell, M Kates, D McConkey, D Pardoll, W Bishai, T Bivalacqua
Nature Communications 2022
From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).
Deininger S, Törzsök P, Mitterberger M, Pallauf M, Oswald D, Deininger C, Lusuardi L
Cancers 2022
Virulence Mechanisms of Mycobacterium abscessus: Current Knowledge and Implications for Vaccine Design
Ferrell KC, Johansen MD, Triccas JA, Counoupas C
Frontiers in microbiology 2022
Optimizing the Boosting Schedule of Subunit Vaccines Consisting of BCG and “Non-BCG” Antigens to Induce Long-Term Immune Memory
Lv W, He P, Ma Y, Tan D, Li F, Xie T, Han J, Wang J, Mi Y, Niu H, Zhu B
Frontiers in immunology 2022
Design and Characterization of a Recombinant Brucella abortus RB51 Vaccine That Elicits Enhanced T Cell-Mediated Immune Response
Sarmadi M, Gheibi A, Khanahmad H, Khorramizadeh MR, Hejazi SH, Zahedi N, Mianesaz H, Kashfi K
Human vaccines 2022
Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
Dockrell HM, McShane H
EBioMedicine 2022
Listeria-Vectored Multiantigenic Tuberculosis Vaccine Enhances Protective Immunity against Aerosol Challenge with Virulent Mycobacterium tuberculosis in BCG-Immunized C57BL/6 and BALB/c Mice
Jia Q, Masleša-Galić S, Nava S, Horwitz MA
mBio 2022
Recombinant BCG to Enhance Its Immunomodulatory Activities
Kowalewicz-Kulbat M, Locht C
Human vaccines 2022
Pathological and protective roles of dendritic cells in Mycobacterium tuberculosis infection: Interaction between host immune responses and pathogen evasion
Kim H, Shin SJ
Frontiers in Cellular and Infection Microbiology 2022
Replication-Deficient Lymphocytic Choriomeningitis Virus-Vectored Vaccine Candidate for the Induction of T Cell Immunity against Mycobacterium tuberculosis
Belnoue E, Vogelzang A, Nieuwenhuizen NE, Krzyzaniak MA, Darbre S, Kreutzfeldt M, Wagner I, Merkler D, Lambert PH, Kaufmann SH, Siegrist CA, Pinschewer DD
International journal of molecular sciences 2022
Highlights of the 3rd international BCG symposium: 100th anniversary of the first administration of BCG
Locht C
Microbes and Infection 2022
A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19.
Singh S, Saavedra-Avila NA, Tiwari S, Porcelli SA
Frontiers in immunology 2022
BCGΔBCG1419c increased memory CD8+ T cell-associated immunogenicity and mitigated pulmonary inflammation compared with BCG in a model of chronic tuberculosis.
Kwon KW, Aceves-Sánchez MJ, Segura-Cerda CA, Choi E, Bielefeldt-Ohmann H, Shin SJ, Flores-Valdez MA
Scientific Reports 2022
Vaccine-Induced Subcutaneous Granulomas in Goats Reflect Differences in Host–Mycobacterium Interactions between BCG- and Recombinant BCG-Derivative Vaccines
Liebler-Tenorio EM, Heyl J, Wedlich N, Figl J, Köhler H, Krishnamoorthy G, Nieuwenhuizen NE, Grode L, Kaufmann SH, Menge C
International journal of molecular sciences 2022
Recent Developments in Mycobacteria-Based Live Attenuated Vaccine Candidates for Tuberculosis
Flores-Valdez MA, Kupz A, Subbian S
Biomedicines 2022
Fighting Tuberculosis: In Search of a BCG Replacement
Nadolinskaia NI, Kotliarova MS, Goncharenko AV
Microorganisms 2022
The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview
E Mouhoub, P Domenech, M Ndao, MB Reed
Frontiers in microbiology 2021
Vaccine Development Against Tuberculosis Over the Last 140 Years: Failure as Part of Success
SH Kaufmann
Frontiers in microbiology 2021
COVID-19 and Beyond: Exploring Public Health Benefits from Non-Specific Effects of BCG Vaccination
KJ Koster, HL Webb, JD Cirillo
Microorganisms 2021
A review of the BCG vaccine and other approaches toward tuberculosis eradication
T Cho, C Khatchadourian, H Nguyen, Y Dara, S Jung, V Venketaraman
Human Vaccines & Immunotherapeutics 2021
Type I interferon decreases macrophage energy metabolism during mycobacterial infection
GS Olson, TA Murray, AN Jahn, D Mai, AH Diercks, ES Gold, A Aderem
Cell Reports 2021
Insights into the molecular determinants involved in Mycobacterium tuberculosis persistence and their therapeutic implications
H Joshi, D Kandari, R Bhatnagar
Virulence 2021
Vaccine Design: Methods and Protocols, Volume 1. Vaccines for Human Diseases
S Thomas
2021
Effect of transgenic Leishmania major expressing mLLO-Bax-Smac fusion gene in the apoptosis of the infected macrophages.
Aghaei M, Khanahmad H, Jalali A, Aghaei S, Narimani M, Hosseini SM, Namdar F, Hejazi SH
Iranian Journal of Basic Medical Sciences 2021
Mucosal delivery of ESX-1–expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes
HD Sathkumara, V Muruganandah, MM Cooper, MA Field, A Alim, R Brosch, N Ketheesan, B Govan, CM Rush, L Henning, A Kupz
Proceedings of the National Academy of Sciences 2020
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy
CA Rentsch, P Bosshard, G Mayor, M Rieken, H Püschel, G Wirth, R Cathomas, GP Parzmair, L Grode, B Eisele, H Sharma, M Gupta, S Gairola, U Shaligram, D Goldenberger, F Spertini, R Audran, M Enoiu, S Berardi, S Hayoz, A Wicki
OncoImmunology 2020
Towards new TB vaccines
B Brazier, H McShane
Seminars in Immunopathology 2020
Vaccine strategies for the Mtb/HIV copandemic
R Sharan, D Kaushal
npj Vaccines 2020
Clinical Development of New TB Vaccines: Recent Advances and Next Steps
M Hatherill, RG White, TR Hawn
Frontiers in microbiology 2020
Luteolin-mediated Kv1.3 K+ channel inhibition augments BCG vaccine efficacy against tuberculosis by promoting central memory T cell responses in mice
DK Singh, VP Dwivedi, SP Singh, A Kumari, SK Sharma, A Ranganathan, LV Kaer, G Das, DM Lewinsohn
PLoS pathogens 2020
Preclinical Progress of Subunit and Live Attenuated Mycobacterium tuberculosis Vaccines: A Review following the First in Human Efficacy Trial
J Watt, J Liu
Pharmaceutics 2020
Tuberculosis vaccine development: from classic to clinical candidates
J Li, A Zhao, J Tang, G Wang, Y Shi, L Zhan, C Qin
European Journal of Clinical Microbiology & Infectious Diseases 2020
Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology
SH Kaufmann
Frontiers in immunology 2020
Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system
NM de Queiroz, FV Marinho, MA Chagas, LC Leite, EJ Homan, MT de Magalhães, SC Oliveira
Microbes and infection / Institut Pasteur 2020
A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
Bagher Moradi, Mojtaba Sankian, Yousef Amini, Aida Gholoobi, Zahra Meshkat
Iranian Journal of Basic Medical Sciences 2020
Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity
L Pöyhönen, J Bustamante, JL Casanova, E Jouanguy, Q Zhang
Journal of Clinical Immunology 2019
MHC‐restricted Ag85B‐specific CD8 + T cells are enhanced by recombinant BCG prime and DNA boost immunization in mice
S KomineAizawa, J Jiang, S Mizuno, S Hayakawa, K Matsuo, LF Boyd, DH Margulies, M Honda
European Journal of Immunology 2019
Tuberculosis Vaccine Development: Progress in Clinical Evaluation
SB Sable, JE Posey, TJ Scriba
Clinical microbiology reviews 2019
Neue Impfstoffe gegen Tuberkulose
SH Kaufmann
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2019
Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria
CC Santos, D Rodriguez, AK Issamu, LC Leite, IP Nascimento
Human Vaccines & Immunotherapeutics 2019
Customizing Host Chromatin: a Bacterial Tale
M Connor, L Arbibe, M Hamon, P Cossart, CR Roy, P Sansonetti
Microbiology spectrum 2019
Development of New Preventive and Therapeutic Vaccines for Tuberculosis
BE Kwon, JH Ahn, S Min, H Kim, J Seo, SG Yeo, HJ Ko
Immune Network 2018
The Profile of T Cell Responses in Bacille Calmette–Guérin-Primed Mice Boosted by a Novel Sendai Virus Vectored Anti-Tuberculosis Vaccine
Z Hu, L Gu, CL Li, T Shu, DB Lowrie, XY Fan
Frontiers in immunology 2018
Consequence of enhanced LC3-trafficking for a live, attenuated M. tuberculosis vaccine
S Köster, T Klevorn, K Papavinasasundaram, CM Sassetti, C Portal-Celhay, JA Philips
Vaccine 2018
Next-Generation Vaccines Based on Bacille Calmette–Guérin
NE Nieuwenhuizen, SH Kaufmann
Frontiers in immunology 2018
The BCGΔBCG1419c Vaccine Candidate Reduces Lung Pathology, IL-6, TNF-α, and IL-10 During Chronic TB Infection
MA Flores-Valdez, C Pedroza-Roldán, M de Jesús Aceves-Sánchez, EJ Peterson, NS Baliga, R Hernández-Pando, JL Troudt, E Creissen, L Izzo, H Bielefeldt-Ohmann, T Bickett, AA Izzo
Frontiers in microbiology 2018
The current status, challenges, and future developments of new tuberculosis vaccines
W Gong, Y Liang, X Wu
Human Vaccines & Immunotherapeutics 2018
Mycobacterium tuberculosis Invasion of the Human Lung: First Contact
J Maertzdorf, M Tönnies, L Lozza, S Schommer-Leitner, H Mollenkopf, TT Bauer, SH Kaufmann
Frontiers in immunology 2018
Recombinant BCG Overexpressing phoP-phoR Confers Enhanced Protection against Tuberculosis
SK Ahn, V Tran, A Leung, M Ng, M Li, J Liu
Molecular Therapy 2018
Characterization of Mycobacterium tuberculosis strains in Beijing, China: drug susceptibility phenotypes and Beijing genotype family transmission
Y Liu, X Zhang, Y Zhang, Y Sun, C Yao, W Wang, C Li
BMC Infectious Diseases 2018
Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1− CD4+ T cells
NC Bull, E Stylianou, DA Kaveh, N Pinpathomrat, J Pasricha, R Harrington-Kandt, MC Garcia-Pelayo, PJ Hogarth, H McShane
Mucosal Immunology 2018
Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
TY Liao, A Lau, J Sunil, V Hytönen, Z Hmama
Journal of visualized experiments : JoVE 2018
The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing
NE Nieuwenhuizen, PS Kulkarni, U Shaligram, MF Cotton, CA Rentsch, B Eisele, L Grode, SH Kaufmann
Frontiers in immunology 2017
Human Immunology of Tuberculosis
TJ Scriba, AK Coussens, HA Fletcher, WR Jacobs, H McShane, V Mizrahi, IM Orme
Microbiology spectrum 2017
Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice
Z Hu, KW Wong, HM Zhao, HL Wen, P Ji, H Ma, K Wu, SH Lu, F Li, ZM Li, T Shu, JQ Xu, DB Lowrie, XY Fan
Molecular Therapy 2017
Immune Responses to Bacillus Calmette–Guérin Vaccination: Why Do They Fail to Protect against Mycobacterium tuberculosis?
JI Moliva, J Turner, JB Torrelles
Frontiers in immunology 2017
Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial
SK Sharma, K Katoch, R Sarin, R Balambal, NK Jain, N Patel, KJ Murthy, N Singla, PK Saha, A Khanna, U Singh, S Kumar, A Sengupta, JN Banavaliker, DS Chauhan, S Sachan, M Wasim, S Tripathi, N Dutt, N Jain, N Joshi, SR Penmesta, S Gaddam, S Gupta, B Khamar, B Dey, DK Mitra, SK Arora, S Bhaskar, R Rani
Scientific Reports 2017
What Have We Learnt about BCG Vaccination in the Last 20 Years?
HM Dockrell, SG Smith
Frontiers in immunology 2017
A Promising Listeria-Vectored Vaccine Induces Th1-Type Immune Responses and Confers Protection Against Tuberculosis
Y Yin, K Lian, D Zhao, C Tao, X Chen, W Tan, X Wang, Z Xu, M Hu, Y Rao, X Zhou, Z Pan, X Zhang, X Jiao
Frontiers in Cellular and Infection Microbiology 2017
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
SH Kaufmann, HM Dockrell, N Drager, MM Ho, H McShane, O Neyrolles, TH Ottenhoff, B Brij, D Roordink, F Spertini, S Stenger, J Thole, FA Verreck, A Williams
Frontiers in immunology 2017
Immunological consequences of strain variation within the Mycobacterium tuberculosis complex
LD Tientcheu, A Koch, M Ndengane, G Andoseh, B Kampmann, RJ Wilkinson
European Journal of Immunology 2017
Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination
MC Haks, B Bottazzi, V Cecchinato, CD Gregorio, GD Giudice, SH Kaufmann, A Lanzavecchia, DJ Lewis, J Maertzdorf, A Mantovani, F Sallusto, M Sironi, M Uguccioni, TH Ottenhoff
Frontiers in immunology 2017
Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity
UE Schaible, L Linnemann, N Redinger, EC Patin, T Dallenga
Frontiers in immunology 2017
Efficacy Testing of H56 cDNA Tattoo Immunization against Tuberculosis in a Mouse Model
AC Platteel, NE Nieuwenhuizen, T Domaszewska, S Schürer, U Zedler, V Brinkmann, AJ Sijts, SH Kaufmann
Frontiers in immunology 2017
Deletion of BCG Hip1 protease enhances dendritic cell and CD4 T cell responses
E Bizzell, JK Sia, M Quezada, A Enriquez, M Georgieva, J Rengarajan
Journal of leukocyte biology 2017
The E3 ubiquitin ligase NEDD4 enhances killing of membrane-perturbing intracellular bacteria by promoting autophagy
G Pei, H Buijze, H Liu, P Moura-Alves, C Goosmann, V Brinkmann, H Kawabe, A Dorhoi, SH Kaufmann
Autophagy 2017
Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG Δ ureC :: hly Improves Protection against Tuberculosis
M Gengenbacher, N Nieuwenhuizen, A Vogelzang, H Liu, P Kaiser, S Schuerer, D Lazar, I Wagner, HJ Mollenkopf, SH Kaufmann
mBio 2016
Innate Immunity Holding the Flanks until Reinforced by Adaptive Immunity against Mycobacterium tuberculosis Infection
N Khan, A Vidyarthi, S Javed, JN Agrewala
Frontiers in microbiology 2016
Manipulation of BCG vaccine: a double-edged sword
VK Singh, R Srivastava, BS Srivastava
European Journal of Clinical Microbiology & Infectious Diseases 2016
Current status of new tuberculosis vaccine in children
Y Pang, A Zhao, C Cohen, W Kang, J Lu, G Wang, Y Zhao, S Zheng
Human Vaccines & Immunotherapeutics 2016
A novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis
KL Griffiths, DO Villarreal, DB Weiner, SA Khader
Human Vaccines & Immunotherapeutics 2016
Loss of Lipid Virulence Factors Reduces the Efficacy of the BCG Vaccine
V Tran, SK Ahn, M Ng, M Li, J Liu
Scientific Reports 2016
Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine
HA Fletcher
mBio 2016
Neonatal Fc Receptor Regulation of Lung Immunoglobulin and CD103 + Dendritic Cells Confers Transient Susceptibility to Tuberculosis
A Vogelzang, L Lozza, ST Reece, C Perdomo, U Zedler, K Hahnke, D Oberbeck-Mueller, A Dorhoi, SH Kaufmann, S Ehrt
Infection and immunity 2016
Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy
KL Griffiths, M Ahmed, S Das, R Gopal, W Horne, TD Connell, KD Moynihan, JK Kolls, DJ Irvine, MN Artyomov, J Rangel-Moreno, SA Khader
Nature Communications 2016
Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection
M Zhang, C Dong, S Xiong
Human Vaccines & Immunotherapeutics 2016
Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa
AG Loxton, JK Knaul, L Grode, A Gutschmidt, C Meller, B Eisele, H Johnstone, G der Spuy, J Maertzdorf, SH Kaufmann, AC Hesseling, G Walzl, MF Cotton, KM Edwards
Clinical and vaccine immunology : CVI 2016
Inhibition of apoptosis by Rv2456c through Nuclear factor-κB extends the survival of Mycobacterium tuberculosis
KL Smith, S Lee
International Journal of Mycobacteriology 2016
Aerosol immunisation for TB: matching route of vaccination to route of infection
ZR Thomas, H McShane
Transactions of the Royal Society of Tropical Medicine and Hygiene 2015
Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?
S Singh, M Kumar, P Singh
Tuberculosis Research and Treatment 2015
CD8 T cells and Mycobacterium tuberculosis infection
PL Lin, JA Flynn
Seminars in Immunopathology 2015
Vaccines for TB: Lessons from the Past Translating into Future Potentials
GJ Tye, MH Lew, YS Choong, TS Lim, ME Sarmiento, A Acosta, MN Norazmi
Journal of Immunology Research 2015
Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency: Acr1 reinvigorates BCG potency
KF Siddiqui, M Amir, N Khan, GR Krishna, JA Sheikh, K Rajagopal, JN Agrewala
Clinical & Experimental Immunology 2015
Recent advances in the diagnosis and treatment of childhood tuberculosis
MK Kumar, P Kumar, A Singh
Journal of Natural Science, Biology, and Medicine 2015
Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: Why does BCG fail to protect against tuberculosis?
JI Moliva, J Turner, JB Torrelles
Vaccine 2015
The Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosis
M Henao-Tamayo, CA Shanley, D Verma, A Zilavy, MC Stapleton, SK Furney, B Podell, IM Orme, TJ Scriba
PloS one 2015
Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines
SG Smith, K Smits, SA Joosten, KE van Meijgaarden, I Satti, HA Fletcher, N Caccamo, F Dieli, F Mascart, H McShane, HM Dockrell, TH Ottenhoff, TJ Scriba
PloS one 2015
Current efforts and future prospects in the development of live mycobacteria as vaccines
TW Ng, NA Saavedra-Ávila, SC Kennedy, LJ Carreño, SA Porcelli
Expert Review of Vaccines 2015
Variable Virulence and Efficacy of BCG Vaccine Strains in Mice and Correlation With Genome Polymorphisms
L Zhang, H Ru, F Chen, C Jin, R Sun, X Fan, M Guo, J Mai, W Xu, Q Lin, J Liu
Molecular Therapy 2015
Improving the Immunogenicity of the Mycobacterium bovis BCG Vaccine by Non-Genetic Bacterial Surface Decoration Using the Avidin-Biotin System
TY Liao, A Lau, S Joseph, V Hytönen, Z Hmama, AK Tyagi
PloS one 2015
A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren
Y Ozeki, M Igarashi, M Doe, A Tamaru, N Kinoshita, Y Ogura, T Iwamoto, R Sawa, M Umekita, S Enany, Y Nishiuchi, M Osada-Oka, T Hayashi, M Niki, Y Tateishi, M Hatano, S Matsumoto, A Rawkins
PloS one 2015
Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis
KB Urdahl
Seminars in Immunology 2014
Interaction of Mycobacterium tuberculosis with Host Cell Death Pathways
L Srinivasan, S Ahlbrand, V Briken
Cold Spring Harbor Perspectives in Medicine 2014
Immunomodulatory effects of recombinant BCG expressing MSP-1C of Plasmodium falciparum on LPS- or LPS+IFN-γ-stimulated J774A.1 cells
D Mohamad, R Suppian, NM Nor
Human Vaccines & Immunotherapeutics 2014
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults
M Hatherill, H Geldenhuys, B Pienaar, S Suliman, P Chheng, SM Debanne, DF Hoft, WH Boom, WA Hanekom, JL Johnson
Vaccine 2014
Novel vaccine approaches for protection against intracellular pathogens
KL Griffiths, SA Khader
Current Opinion in Immunology 2014
A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
H McShane, A Williams
Tuberculosis 2014
Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines
AP Junqueira-Kipnis, LM Neto, A Kipnis
Frontiers in immunology 2014
Incomplete pneumolysin oligomers form membrane pores
AF Sonnen, JM Plitzko, RJ Gilbert
Open Biology 2014
Polyclonal activation of naïve T cells by urease deficient-recombinant BCG that produced protein complex composed of heat shock protein 70, CysO and major membrane protein-II
Y Tsukamoto, Y Maeda, T Tamura, T Mukai, M Makino
BMC Infectious Diseases 2014
Screening of Mycobacterium avium subsp. paratuberculosis mutants for attenuation in a bovine monocyte-derived macrophage model
EA Lamont, AM Talaat, PM Coussens, JP Bannantine, YT Grohn, R Katani, L Li, V Kapur, S Sreevatsan
Frontiers in Cellular and Infection Microbiology 2014
Central Memory CD4+ T Cells Are Responsible for the Recombinant Bacillus Calmette-Guerin  ureC::hly Vaccine's Superior Protection Against Tuberculosis
A Vogelzang, C Perdomo, U Zedler, S Kuhlmann, R Hurwitz, M Gengenbacher, SH Kaufmann
The Journal of Infectious Diseases 2014
Dose of Incorporated Immunodominant Antigen in Recombinant BCG Impacts Modestly on Th1 Immune Response and Protective Efficiency against Mycobacterium tuberculosis in Mice
H Ma, K Wu, F Liu, H Yang, H Kang, NN Chen, Q Yuan, WJ Zhou, XY Fan
Journal of Immunology Research 2014
The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen
R Chapman, WR Bourn, E Shephard, H Stutz, N Douglass, T Mgwebi, A Meyers, N Chin'ombe, AL Williamson
PloS one 2014
Tuberculosis Vaccines and Prevention of Infection
TR Hawn, TA Day, TJ Scriba, M Hatherill, WA Hanekom, TG Evans, GJ Churchyard, JG Kublin, LG Bekker, SG Self
Microbiology and molecular biology reviews : MMBR 2014
Attrition of T-Cell Functions and Simultaneous Upregulation of Inhibitory Markers Correspond with the Waning of BCG-Induced Protection against Tuberculosis in Mice
S Nandakumar, S Kannanganat, JE Posey, RR Amara, SB Sable, TJ Scriba
PloS one 2014
Recent advances towards tuberculosis control: vaccines and biomarkers
JW rd, SH Kaufmann
Journal of Internal Medicine 2014
Improving Mycobacterium bovis Bacillus Calmette-Guèrin as a Vaccine Delivery Vector for Viral Antigens by Incorporation of Glycolipid Activators of NKT Cells
Manjunatha M. Venkataswamy, Tony W. Ng, Shalu S. Kharkwal, Leandro J. Carreño, Alison J. Johnson, Shajo Kunnath-Velayudhan, Zheng Liu, Robert Bittman, Peter J. Jervis, Liam R. Cox, Gurdyal S. Besra, Xiangshu Wen, Weiming Yuan, Moriya Tsuji, Xiangming Li, David D. Ho, John Chan, Sunhee Lee, Richard Frothingham, Barton F. Haynes, Michael W. Panas, Geoffrey O. Gillard, Jaimie D. Sixsmith, Birgit Korioth-Schmitz, Joern E. Schmitz, Michelle H. Larsen, William R. Jacobs Jr, Steven A. Porcelli
PloS one 2014
Tuberculosis Vaccine Types and Timings: FIG 1
IM Orme, CJ Papasian
Clinical and vaccine immunology : CVI 2014
Disclosure of Selective Advantages in the "modern" Sublineage of the Mycobacterium tuberculosis Beijing Genotype Family by Quantitative Proteomics
J Keijzer, PE de Haas, AH de Ru, PA van Veelen, D Soolingen
Molecular & cellular proteomics : MCP 2014
Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations
A Leunda, A Baldo, M Goossens, K Huygen, P Herman, M Romano
Human vaccines 2014
Novel Vaccination Strategies against Tuberculosis
P Andersen, SH Kaufmann
Cold Spring Harbor Perspectives in Medicine 2014
Dietary Pyridoxine Controls Efficacy of Vitamin B6-Auxotrophic Tuberculosis Vaccine Bacillus Calmette-Guerin ureC::hly pdx1 in Mice
M Gengenbacher, A Vogelzang, S Schuerer, D Lazar, P Kaiser, SH Kaufmann
mBio 2014
Vaccine Development for Tuberculosis: Current Progress
IM Orme
Drugs 2013
A Modified Bacillus Calmette-Gu�rin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence
C Shoen, M DeStefano, C Hager, KT Tham, M Braunstein, A Allen, H Gates, M Cynamon, D Kernodle
Human vaccines 2013
The tuberculosis vaccine candidate Bacillus Calmette-Guérin ΔureC::hly coexpressing human interleukin-7 or -18 enhances antigen-specific T cell responses in mice
M Rao, A Vogelzang, P Kaiser, S Schuerer, SH Kaufmann, M Gengenbacher
PloS one 2013
Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells
SL Baldwin, LK Ching, SO Pine, M Moutaftsi, E Lucas, A Vallur, MT Orr, S Bertholet, SG Reed, RN Coler
Journal of immunology (Baltimore, Md. : 1950) 2013
Nonclinical Development of BCG Replacement Vaccine Candidates
K Velmurugan, L Grode, R Chang, M Fitzpatrick, D Laddy, D Hokey, S Derrick, S Morris, D McCown, R Kidd, M Gengenbacher, B Eisele, S Kaufmann, J Fulkerson, M Brennan
Human vaccines 2013
Key Role for the Alternative Sigma Factor, SigH, in the Intracellular Life of Mycobacterium avium subsp. paratuberculosis during Macrophage Stress
P Ghosh, C Wu, AM Talaat, A Camilli
Infection and immunity 2013
Efficient Activation of Human T Cells of Both CD4 and CD8 Subsets by Urease-Deficient Recombinant Mycobacterium bovis BCG That Produced a Heat Shock Protein 70-M. tuberculosis-Derived Major Membrane Protein II Fusion Protein
T Mukai, Y Tsukamoto, Y Maeda, T Tamura, M Makino, WR Waters
Clinical and vaccine immunology : CVI 2013
Priming with a Recombinant Pantothenate Auxotroph of Mycobacterium bovis BCG and Boosting with MVA Elicits HIV-1 Gag Specific CD8+ T Cells
R Chapman, E Shephard, H Stutz, N Douglass, V Sambandamurthy, I Garcia, B Ryffel, W Jacobs, AL Williamson, TM Doherty
PloS one 2012
OX40 Ligand Fusion Protein Delivered Simultaneously With the BCG Vaccine Provides Superior Protection Against Murine Mycobacterium tuberculosis Infection
RJ Snelgrove, MM Cornere, L Edwards, B Dagg, J Keeble, A Rodgers, DE Lyonga, GR Stewart, DB Young, B Walker, T Hussell
The Journal of Infectious Diseases 2012
Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis
MJ Brennan, B Clagett, H Fitzgerald, V Chen, A Williams, AA Izzo, LF Barker
Vaccine 2012
Mycobacterium tuberculosis: success through dormancy
M Gengenbacher, SH Kaufmann
FEMS Microbiology Reviews 2012
Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
TH Ottenhoff, SH Kaufmann
PLoS pathogens 2012
Formulation of a mmaA4 Gene Deletion Mutant of Mycobacterium bovis BCG in Cationic Liposomes Significantly Enhances Protection against Tuberculosis
SC Derrick, D Dao, A Yang, K Kolibab, WR Jacobs, SL Morris
PloS one 2012
Escape from the Phagosome: The Explanation for MHC-I Processing of Mycobacterial Antigens?
MJ Harriff, GE Purdy, DM Lewinsohn
Frontiers in immunology 2012
The Secreted Lipoprotein, MPT83, of Mycobacterium tuberculosis Is Recognized during Human Tuberculosis and Stimulates Protective Immunity in Mice
FF Kao, S Mahmuda, R Pinto, JA Triccas, NP West, WJ Britton
PloS one 2012
The fbpA/sapM Double Knock Out Strain of Mycobacterium tuberculosis Is Highly Attenuated and Immunogenic in Macrophages
S Saikolappan, J Estrella, SJ Sasindran, A Khan, LY Armitige, C Jagannath, S Dhandayuthapani
PloS one 2012
Mycobacterium tuberculosis Beijing Strains Favor Transmission but Not Drug Resistance in China
C Yang, T Luo, G Sun, K Qiao, G Sun, K DeRiemer, J Mei, Q Gao
Clinical Infectious Diseases 2012
Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis: Translational advances for MDR/XDR-TB
ND Walter, M Strong, R Belknap, DJ Ordway, CL Daley, ED Chan
Respirology 2012
Prime-boost approaches to tuberculosis vaccine development
N Dalmia, AJ Ramsay
Expert Review of Vaccines 2012
Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice
J Wang, Y Qie, W Liu, H Wang
Human Vaccines & Immunotherapeutics 2012
Urease Activity Represents an Alternative Pathway for Mycobacterium tuberculosis Nitrogen Metabolism
W Lin, V Mathys, EL Ang, VH Koh, JM Gómez, ML Ang, SZ Rahim, MP Tan, K Pethe, S Alonso, JL Flynn
Infection and immunity 2012
Prime-Boost Vaccination with rBCG/rAd35 Enhances CD8+ Cytolytic T-Cell Responses in Lesions from Mycobacterium Tuberculosis-Infected Primates
S Rahman, I Magalhaes, J Rahman, RK Ahmed, DR Sizemore, CA Scanga, F Weichold, F Verreck, I Kondova, J Sadoff, R Thorstensson, M Spångberg, M Svensson, J Andersson, M Maeurer, S Brighenti
Molecular Medicine 2012
Recombinant vaccines and the development of new vaccine strategies.
Nascimento IP, Leite LC
2012
Advances in the Diagnosis, Treatment and Control of HIV Associated Tuberculosis
Kirenga BJ, Chanda DM, Muwonge CM, Yimer G, Adatu FE, Onyebujoh PC
African Journal of Infectious Diseases 2012
Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis
J Hinchey, BY Jeon, H Alley, B Chen, M Goldberg, S Derrick, S Morris, WR Jacobs, SA Porcelli, S Lee
PloS one 2011
Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis
N Festjens, P Bogaert, A Batni, E Houthuys, E Plets, D Vanderschaeghe, B Laukens, B Asselbergh, E Parthoens, RD Rycke, MA Willart, P Jacques, D Elewaut, P Brouckaert, BN Lambrecht, K Huygen, N Callewaert
EMBO Molecular Medicine 2011
Tuberculosis vaccines in clinical trials
R Rowland, H McShane
Expert Review of Vaccines 2011
Development of new vaccines and drugs for TB: limitations and potential strategic errors
IM Orme
Future Microbiology 2011
BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity
A Keyser, JL Troudt, JL Taylor, AA Izzo
Vaccine 2011
Co-Immunization of Plasmid DNA Encoding IL-12 and IL-18 with Bacillus Calmette-Guérin Vaccine against Progressive Tuberculosis
BY Jeon, H Eoh, SJ Ha, H Bang, SC Kim, YC Sung, SN Cho
Yonsei Medical Journal 2011
Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate
SL Sampson, KG Mansfield, A Carville, DM Magee, T Quitugua, EW Howerth, BR Bloom, MK Hondalus
Vaccine 2011
Investigation on Mycobacterium tuberculosis Diversity in China and the Origin of the Beijing Clade
K Wan, J Liu, Y Hauck, Y Zhang, J Liu, X Zhao, Z Liu, B Lu, H Dong, Y Jiang, K Kremer, G Vergnaud, D Soolingen, C Pourcel
PloS one 2011
Bacillus Calmette-Guérin Vaccination Using a Microneedle Patch
Y Hiraishi, S Nandakumar, SO Choi, JW Lee, YC Kim, JE Posey, SB Sable, MR Prausnitz
Vaccine 2011
Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses
C Desel, A Dorhoi, S Bandermann, L Grode, B Eisele, SH Kaufmann
The Journal of Infectious Diseases 2011
Tuberculosis vaccines: beyond bacille Calmette–Guérin
H McShane
Philosophical Transactions of the Royal Society B: Biological Sciences 2011
Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control
K Matsuo, Y Yasutomi
Tuberculosis Research and Treatment 2011
The impact of alcohol on BCG-induced immunity against Mycobacterium tuberculosis
E Porretta, KI Happel, XS Teng, A Ramsay, CM Mason
Alcoholism, clinical and experimental research 2011
Vaccines and global health
B Greenwood, D Salisbury, AV Hill
Philosophical Transactions of the Royal Society B: Biological Sciences 2011
Mycobacterium bovis BCG-Mediated Protection against W-Beijing Strains of Mycobacterium tuberculosis Is Diminished Concomitant with the Emergence of Regulatory T Cells
DJ Ordway, S Shang, M Henao-Tamayo, A Obregon-Henao, L Nold, M Caraway, CA Shanley, RJ Basaraba, CG Duncan, IM Orme
Clinical and vaccine immunology : CVI 2011
Relief from Zmp1-Mediated Arrest of Phagosome Maturation Is Associated with Facilitated Presentation and Enhanced Immunogenicity of Mycobacterial Antigens
P Johansen, A Fettelschoss, B Amstutz, P Selchow, Y Waeckerle-Men, P Keller, V Deretic, L Held, TM Kündig, EC Böttger, P Sander
Clinical and vaccine immunology : CVI 2011
Tuberculosis vaccine promises sterilizing immunity
H McShane, A Williams
Nature Medicine 2011
Induction of Specific CD8 T Cells against Intracellular Bacteria by CD8 T-Cell-Oriented Immunization Approaches
T Nagata, Y Koide
Journal of biomedicine & biotechnology 2010
The immunology of tuberculosis: From bench to bedside
K DHEDA, SK SCHWANDER, B ZHU, RN van ZYL-SMIT, Y ZHANG
Respirology 2010
Mycobacterial nucleoside diphosphate kinase blocks phagosome maturation in murine RAW 264.7 macrophages
J Sun, X Wang, A Lau, TY Liao, C Bucci, Z Hmama
PloS one 2010
Protective efficacy of BCG overexpressing an L,D-transpeptidase against M. tuberculosis infection
ST Nolan, G Lamichhane
PloS one 2010
Fidelity of pathogen-specific CD4+ T cells to the Th1 lineage is controlled by exogenous cytokines, interferon-gamma expression, and pathogen lifestyle
MM Curtis, E Rowell, S Shafiani, A Negash, KB Urdahl, CB Wilson, SS Way
Cell Host & Microbe 2010
Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model
RS Kashyap, AA Husain, SH Morey, MS Panchbhai, PS Deshpande, HJ Purohit, GM Taori, HF Daginawala
Journal of immune based therapies and vaccines 2010
Tuberculosis: what we don't know can, and does, hurt us
DG Russell, CE 3rd, JA Flynn
Science (New York, N.Y.) 2010
The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses
PD Hulseberg, A Zozulya, HH Chu, JA Triccas, Z Fabry, M Sandor
Immunology Letters 2010
Recombinant BCG as a vaccine vehicle to protect against tuberculosis
JA Triccas
Bioengineered bugs 2010
New approaches in the diagnosis and treatment of latent tuberculosis infection
S Ahmad
Respiratory Research 2010
Immunostimulatory Activity of Major Membrane Protein II from Mycobacterium tuberculosis
Y Tsukamoto, M Endoh, T Mukai, Y Maeda, T Tamura, M Kai, M Makino
Clinical and vaccine immunology : CVI 2010
Strains of the East Asian (W/Beijing) Lineage of Mycobacterium tuberculosis Are DosS/DosT-DosR Two-Component Regulatory System Natural Mutants
A Fallow, P Domenech, MB Reed
Journal of bacteriology 2010
Safety and Immunogenicity of Novel Recombinant BCG and Modified Vaccinia Virus Ankara Vaccines in Neonate Rhesus Macaques
M Rosario, J Fulkerson, S Soneji, J Parker, EJ Im, N Borthwick, A Bridgeman, C Bourne, J Joseph, JC Sadoff, T Hanke
Journal of virology 2010
Surface Expression of MPT64 as a Fusion with the PE Domain of PE_PGRS33 Enhances Mycobacterium bovis BCG Protective Activity against Mycobacterium tuberculosis in Mice
M Sali, GD Sante, A Cascioferro, A Zumbo, C Nicolò, V Donà, S Rocca, A Procoli, M Morandi, F Ria, G Palù, G Fadda, R Manganelli, G Delogu
Infection and immunity 2010
Novel Recombinant Mycobacterium bovis BCG, Ovine Atadenovirus, and Modified Vaccinia Virus Ankara Vaccines Combine To Induce Robust Human Immunodeficiency Virus-Specific CD4 and CD8 T-Cell Responses in Rhesus Macaques
M Rosario, R Hopkins, J Fulkerson, N Borthwick, MF Quigley, J Joseph, DC Douek, HY Greenaway, V Venturi, E Gostick, DA Price, GW Both, JC Sadoff, T Hanke
Journal of virology 2010
Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.
Chapman R, Chege G, Shephard E, Stutz H, Williamson AL
Current HIV research 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009
Macrophage apoptosis in tuberculosis
J Lee, M Hartman, H Kornfeld
Yonsei Medical Journal 2009
Cell-Mediated Immune Responses in Tuberculosis
AM Cooper
Annual Review of Immunology 2009
Incorporation of NKT Cell-Activating Glycolipids Enhances Immunogenicity and Vaccine Efficacy of Mycobacterium bovis Bacillus Calmette-Guérin
MM Venkataswamy, A Baena, MF Goldberg, G Bricard, JS Im, J Chan, F Reddington, GS Besra, WR Jacobs, SA Porcelli
Journal of immunology (Baltimore, Md. : 1950) 2009
Evasion and subversion of antigen presentation by Mycobacterium tuberculosis
A Baena, SA Porcelli
Tissue Antigens 2009
Analysis of predicted CD8+ T cell epitopes from proteins encoded by the specific RD regions of Mycobacterium tuberculosis for vaccine development and specific diagnosis
J Wang, H Zhang, H Wang
Molecular Biology Reports 2009
Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant Δ ureC hly+Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis
EZ Tchilian, C Desel, EK Forbes, S Bandermann, CR Sander, AV Hill, H McShane, SH Kaufmann
Infection and immunity 2009
Acid Resistance in Mycobacterium tuberculosis
OH Vandal, CF Nathan, S Ehrt
Journal of bacteriology 2009
Recombinant Mycobacterium bovis BCG Expressing the Chimeric Protein of Antigen 85B and ESAT-6 Enhances the Th1 Cell-Mediated Response
Y Xu, W Liu, H Shen, J Yan, D Qu, H Wang
Clinical and vaccine immunology : CVI 2009
Confronting the Scientific Obstacles to Global Control of Tuberculosis
Douglas B. Young1, Mark D. Perkins2, Ken Duncan3, Clifton E. Barry, III4
Journal of Clinical Investigation 2008
A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG
MV Tullius, G Harth, S Maslesa-Galic, BJ Dillon, MA Horwitz
Infection and immunity 2008
Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung
R Jain, B Dey, N Dhar, V Rao, R Singh, UD Gupta, VM Katoch, VD Ramanathan, AK Tyagi
PloS one 2008
rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector
I Magalhaes, DR Sizemore, RK Ahmed, S Mueller, L Wehlin, C Scanga, F Weichold, G Schirru, MG Pau, J Goudsmit, S Kühlmann-Berenzon, M Spångberg, J Andersson, H Gaines, R Thorstensson, YA Skeiky, J Sadoff, M Maeurer
PloS one 2008
Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens
KC el Kasmi, JE Qualls, JT Pesce, AM Smith, RW Thompson, M Henao-Tamayo, RJ Basaraba, T König, U Schleicher, MS Koo, G Kaplan, KA Fitzgerald, EI Tuomanen, IM Orme, TD Kanneganti, C Bogdan, TA Wynn, PJ Murray
Nature Immunology 2008
Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines
T Cohen, C Colijn, M Murray
Proceedings of the National Academy of Sciences 2008
A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers
DF Hoft, A Blazevic, G Abate, WA Hanekom, G Kaplan, JH Soler, F Weichold, L Geiter, JC Sadoff, MA Horwitz
The Journal of Infectious Diseases 2008
Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection
AM Gallegos, EG Pamer, MS Glickman
Journal of Experimental Medicine 2008
Living on the edge: inhibition of host cell apoptosis by Mycobacterium tuberculosis
V Briken, JL Miller
Future Microbiology 2008
Biotechnological applications ofListeria's sophisticated infection strategies
S Barbuddhe, T Chakraborty
Microbial Biotechnology 2008
Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis
Joseph Hinchey, Sunhee Lee, Bo Y. Jeon, Randall J. Basaraba, Manjunatha M. Venkataswamy, Bing Chen, John Chan, Miriam Braunstein, Ian M. Orme, Steven C. Derrick, Sheldon L. Morris, William R. Jacobs, Jr., and Steven A. Porcelli
Journal of Clinical Investigation 2007
New TB vaccines: is there a requirement for CD8+ T cells?
W. Henry Boom
Journal of Clinical Investigation 2007
Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis
C Sander, H McShane
Clinical & Experimental Immunology 2007
Next generation: tuberculosis vaccines that elicit protective CD8+ T cells
SM Behar, JS Woodworth, Y Wu
Expert Review of Vaccines 2007
Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection
DM da Fonseca, CL Silva, MO Paula, EG Soares, G Marchal, C Horn, VL Bonato
Immunology 2007
BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease
L Tsenova, R Harbacheuski, N Sung, E Ellison, D Fallows, G Kaplan
Vaccine 2007
A Booster Vaccination with Mycobacterium bovis BCG Does Not Increase the Protective Effect of the Vaccine against Experimental Mycobacterium ulcerans Infection in Mice
A Tanghe, PY Adnet, T Gartner, K Huygen
Infection and immunity 2007
The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis
CS Andersen, J Dietrich, EM Agger, NY Lycke, K Lövgren, P Andersen
Infection and immunity 2007
Mycobacterium tuberculosis nuoG Is a Virulence Gene That Inhibits Apoptosis of Infected Host Cells
K Velmurugan, B Chen, JL Miller, S Azogue, S Gurses, T Hsu, M Glickman, WR Jacobs, SA Porcelli, V Briken, W Bishai
PLoS pathogens 2007
Molecular epidemiology of tuberculosis: current insights
B Mathema, NE Kurepina, PJ Bifani, BN Kreiswirth
Clinical microbiology reviews 2006
New developments in BCG vaccine: implications for tuberculosis control
CR MacIntyre
Epidemiology and Infection 2006
The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link?
F Abebe, G Bjune
Clinical & Experimental Immunology 2006
Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes
JA Carrero, B Calderon, ER Unanue
Journal of Experimental Medicine 2006
Immunostimulatory Activity of Recombinant Mycobacterium bovis BCG That Secretes Major Membrane Protein II of Mycobacterium leprae
M Makino, Y Maeda, K Inagaki
Infection and immunity 2006
Mycobacterium tuberculosis and the host response
SH Kaufmann, ST Cole, V Mizrahi, E Rubin, C Nathan
Journal of Experimental Medicine 2005

← Previous 1 2 3 … 9 10 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Referenced in 1 policy sources
Referenced in 25 patents
Referenced in 3 Wikipedia pages
Highlighted by 1 platforms
226 readers on Mendeley
1 readers on CiteULike
See more details